Mar 17, 2026

Semaglutide Helps a Specific Kind of HFpEF—Not All

Semaglutide improved symptoms and walking capacity in obesity-related HFpEF, but the evidence does not support cardiac use for every patient—or biohacker.

heart failurehfpefsemaglutide

Read article →

Mar 15, 2026

Menopause Heart Risk: Why Your LE8 Trend Matters

A SWAN study links Life's Essential 8 trends through menopause with vascular aging, heart events, and mortality. Learn which metrics deserve attention.

life's essential 8cardiovascular healthmenopause

Read article →

Mar 15, 2026

High-Resistance IMST for Blood Pressure: What We Know

Can five minutes of high-resistance inspiratory muscle training lower blood pressure? A small sham-controlled trial says yes, but replication and safety limits matter.

blood pressureimstendothelial function

Read article →

Mar 14, 2026

Which Mind-Body Practices May Lower Blood Pressure?

New network meta-analyses separate pranayama, meditation, qigong, and tai chi for hypertension. The rankings are intriguing, but far from settled.

hypertensionpranayamablood pressure

Read article →

Mar 13, 2026

Gum Disease and Heart Risk: What the Evidence Actually Shows

Periodontitis tracks with higher cardiovascular risk and faster biological aging. Learn what treatment can change, and why antiseptic mouthwash complicates the story.

periodontitisporphyromonas gingivalisatherosclerosis

Read article →

Mar 11, 2026

Sauna and Heat Therapy Lower Blood Pressure—Modestly

Two RCT meta-analyses find regular sauna and passive heat therapy lower blood pressure by about 4 mmHg, but broader benefits remain unproven.

saunaheat therapyblood pressure

Read article →

Mar 1, 2026

GLP-1s Cut Heart Failure Risk Only in Obesity

GLP-1 drugs lower cardiovascular death broadly, but heart failure hospitalization benefit appears limited to obesity-driven disease.

glp-1heart failureobesity

Read article →

Feb 28, 2026

GLP-1 Drugs in Obese Heart Failure: Where the Benefit Is

A 2025 meta-analysis suggests GLP-1 drugs help some obese heart failure patients, but the signal looks strongest in HFpEF, not HFrEF.

semaglutideglp-1 agonistsheart failure

Read article →

Feb 28, 2026

GLP-1 Drugs in Heart Failure: Real Promise, Tight Limits

Meta-analyses suggest GLP-1 drugs help obese patients with HFpEF feel and function better, but no trial has shown longer survival or clear benefit in HFrEF.

glp-1 agonistsheart failuresemaglutide

Read article →

← PreviousPage 2 of 2